|Bid||1.2300 x 1300|
|Ask||1.2400 x 2200|
|Day's Range||1.2050 - 1.2400|
|52 Week Range||0.2200 - 1.4900|
|Beta (3Y Monthly)||1.84|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Cassava Sciences, Inc. (SAVA), a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, today announced that clinical results of its Phase 2a study of PTI-125 have been selected as a late-breaking oral presentation by the 12th International Conference on Clinical Trials on Alzheimer’s Disease (CTAD). CTAD is a prestigious annual conference focused on Alzheimer’s research and development and takes place this year in San Diego, CA, on December 4-7th, 2019. PTI-125 is Cassava Sciences’ lead drug candidate for Alzheimer’s disease.
PTI-125 is a small molecule that targets the massive neuroinflammation and neurodegeneration observed in the Alzheimer’s brain. In conjunction with the initiation of this Phase 2b study, Cassava Sciences also reported dosing of the first two patients for this study, both of which were uneventful. This Phase 2b study is supported by a research grant award from the National Institutes of Health (NIH).
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. ACADIA Pharmaceuticals (NASDAQ: ACAD ) shares ...
Lead drug candidate, PTI-125, significantly decreased key biomarkers of neuroinflammation and neurodegeneration in all study patients (p
If you're interested in Cassava Sciences, Inc. (NASDAQ:SAVA), then you might want to consider its beta (a measure of...
AUSTIN, Texas, Sept. 03, 2019 -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, announced today that Remi Barbier, President & CEO, will.
AUSTIN, Texas, Aug. 12, 2019 -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biopharmaceutical company developing PTI-125 for Alzheimer’s disease, today reported.
Every investor in Cassava Sciences, Inc. (NASDAQ:SAVA) should be aware of the most powerful shareholder groups...
Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company, announced today that Remi Barbier, its President and CEO, will present at Maxim Group’s conference on Alzheimer’s disease on Wednesday, June 26th, in New York. Maxim’s conference for investors, titled “Alzheimer’s Disease – What’s Next? Treating Alzheimer’s in a Post-Amyloid World”, will be held at their corporate offices at 405 Lexington Ave in New York. Cassava Sciences’ presentation for this conference is now available on the Company’s website under https://www.cassavasciences.com/company-presentations.
Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company, announced today the launch of its newly designed website, www.CassavaSciences.com. Cassava Sciences’ new website has extensive information on Alzheimer’s disease, a key focus of the Company’s research and development. Cassava Sciences expects to announce results of its Phase2a study in the second half of 2019, after patient data are analyzed.
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
AUSTIN, Texas, April 29, 2019 -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biopharmaceutical company, today reported financial results for the first quarter ended March 31,.
Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company, announced the completion of patient enrollment in a clinical study evaluating the safety of its investigational drug, PTI-125, in patients with Alzheimer’s disease. Cassava Sciences is conducting this Phase 2a study with scientific and financial support from the National Institutes of Health (NIH).